SPEAKERS FROM DIAMYD MEDICAL
Born in 1975, Ulf Hannelius earned his Master degree in Biochemistry from the University of Helsinki, Finland and his PhD in Molecular Biology from Karolinska Institutet in Stockholm, Sweden.
In parallel to his postdoctoral research in cancer genomics at the Karolinska Institutet, he completed an Executive MBA at the Stockholm School of Economics and went on to establish his own consultancy company within strategy, market research and innovation management.
Ulf joined Diamyd Medical in 2015 and has served as its CEO since 2016. He is also the board member of Sweden and Silicon Valley based deep tech company MainlyAI. He has coauthored 16 peer reviewed scientific articles during his time in academia and at Diamyd Medical.
Professor Johnny Ludvigsson has been researching diabetes for over 50 years since his first experiments in 1967, and he continues his research today. He is Honorary Member of The European Association for the Study of Diabetes (EASD) and The International Society for Pediatric and Adolescent Diabetes (ISPAD). He has received several awards (eg the Inaugural ISPAD Prize). In the 1990s he initiated the ABIS birth cohort study, which follows 17,000 individuals to investigate the impact of environmental and genetic factors on the development of Type 1 diabetes.
To create resources for diabetes research, Professor Johnny Ludvigsson founded the Swedish Child Diabetes Foundation in 1989. To date, he has published more than 500 articles and participated in a large number of immune interventions with antiCD3, TNF-alfa inhibition and GAD65, one of the major autoantigens in type 1 diabetes and the active ingredient in the antigen-specific immunotherapy Diamyd®.
Professor Johnny Ludvigsson is the principal investigator of the precision medicine Phase III clinical trial Diagnode-3, evaluating the effectiveness of preserving insulin production in adolescents and adults recently diagnosed with Type 1 Diabetes, carrying the genetic HLA DR3-DQ2 haplotype. The trial involves the administration of Diamyd® (GAD-alum) directly into lymph nodes.
Dr. Karin Rosén is an accomplished life sciences executive and physician with over two decades of experience in the biotechnology industry. She has held senior leadership positions at several global companies, including GlaxoSmithKline, Aimmune Therapeutics, Genentech, and Horizon Therapeutics.
Dr. Rosén has an impressive track record in developing and launching novel therapeutics, with expertise in clinical research and development, as well as regulatory filing strategies. She holds experience in developing Phase 2-3 clinical programs for multiple biologics including in the areas of immunology.
As an adjunct member of the Diamyd Medical Board of Director, she brings her extensive experience in global clinical development and U.S. and global medical affairs, making her a valuable addition to the Board and Company.